When was Crossject founded?

Crossject was founded in 2001 and raised its 1st funding round within a year of its incorporation.

Where is Crossject located?

Crossject is headquartered in Dijon, France.

Who is the current CEO of Crossject?

Patrick Alexandre of Crossject.

How many employees does Crossject have?

As of Jul 31, 2026, the latest employee count at Crossject is 98.

Is Crossject a funded company?

Crossject is a funded company, having raised a total of $40.3M across 6 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on May 2001.

When was the latest funding round of Crossject?

Crossject's latest funding was a $***** Grant (prize money) round on Aug 01, 2019, with participation from 1 investor.

Where does Crossject rank among its competitors?

Crossject ranks 1st amongst 32 active competitors, of which 7 are funded. It stands 3rd in terms of total funding among its competitors. The most recent competitor to raise funding was Pirouette Pharma, which secured $1.08M in Mar, 2026.

Who are the top competitors of Crossject?

Crossject's top competitors include Xeris Pharmaceuticals, Windgap Medical and Eveon. Among them, Pirouette Pharma secured the most recent funding round in March, 2026.

Crossject - 2026 Company Profile, Team, Funding & Competitors

Company Details

CROSSJECT developed a needle-free injection platform called Zeneo, which is designed to improve patient’s safety, claimed to provide comfort and to enable a better observance of treatments. The product is a pre-fillable, needle-free injection system that is claimed to deliver drugs intradermally, subcutaneously, and intramuscularly, the company is developing a portfolio of products combining well-known drugs with an innovative injection mode, particularly adapted to emergency situations and most chronic treatments, with a device adaptable to many specific situations.

Website: crossject.com/en/
Social
Email ID: *****@crossject.com

Key Metrics

Founded Year

2001

Location

Dijon, France

Stage

Public

Total Funding

$40.3M in 6 rounds

Latest Funding Round

Grant (prize money), Aug 01, 2019, $*****

Investors

GSK & 6 more

Ranked

1^st among 32 active competitors

Employee Count

98 as on Jul 31, 2026

Similar Companies

Xeris Pharmaceuticals & 31 more

Exit Details

Public

View Crossject's full profile

Crossject got listed on Feb 20, 2014.

Click here to take a look at Crossject's IPO in detail

Crossject has raised a total funding of $40.3M over 6 rounds. Its first funding round was on May 2001. Its latest funding round was a Grant (prize money) round on Aug 01, 2019 for $*****. 1 investor participated in its latest round. Crossject has 7 institutional investors.

Here is the list of recent funding rounds of Crossject:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Aug 01, 2019	3248599	Grant (prize money)	3963584	2425190	9036460	1905494
Jul 09, 2013	1894464	Series A	9466995	9299835	4820902	A Plus Finance & 2 more
Mar 15, 2010	8528254	Series A	1579254	5564654	GSK	4862803

Access funding benchmarks and valuations. Sign up today!

View details of Crossject's funding rounds and investors

The founders of Crossject are Xaviere Castano and Patrick Alexandre.

Here are the details of Crossject's key team members:

Xaviere Castano: Co-Founder of Crossject.
Patrick Alexandre: Co-Founder & CEO of Crossject.

View details of Crossject's Founder profiles and Board Members

Crossject's employee count trend

Crossject has 98 employees as of Jul 26. Here is Crossject's employee count trend over the years:

Uncover Crossject's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Crossject include Xeris Pharmaceuticals, Windgap Medical and Eveon. Here is the list of Top 10 competitors of Crossject, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Crossject 2001, Dijon (France), Public	Needle-free self-injectable drugs	$40.3M	Rothschild & Co, Sofimac Investment Managers ... & 5 others	60/100
2nd	Xeris Pharmaceuticals 2005, Chicago (United States), Public	Developer of liquid-stable injectables for the delivery of drugs	$155M	Redmile Group, Central Texas Angel Network ... & 18 others	60/100
3rd	Windgap Medical 2011, Boston (United States), Series B	Provider of drug delivery autoinjector for the treatment of anaphylaxis	$76.7M	Taiwania Capital, SKK & 11 others	44/100
4th	Eveon 2009, Montbonnot Saint Martin (France), Seed	Manufacture of connected medical devices focused on the preparation and administration of therapeutic treatment	$4.05M	MEDEVICE, Credit Agricole Alpes Developpement ... & 1 others	42/100
5th	MIT 1978, Montreal (Canada), Public	Provider of needleless injectors for various medical applications	-	-	36/100
6th	Qlibrium 2014, Woburn (United States), Funding Raised	Provider of on‑body drug delivery systems	-	JLABS, Taihill Venture & 1 others	36/100
7th	Cellular Vehicles 2021, San Mateo (United States), Funding Raised	Developer of process automation tools for cell-based therapy manufacturing	-	HHS, Boost VC	34/100
8th	Asan Therapeutics Boston (United States), Unfunded	Developer of drug delivery technology to treat cancer patients	-	-	32/100
9th	Pirouette Pharma 2021, Portsmouth (United States), Seed	Developer of auto-injector technology for injectable medicines and partner programs	$3.43M	HHS, Founders	31/100
10th	zephyrusinnovations.com 2022, Vancouver (Canada), Seed	Manufacturer of safety syringes and closed system transfer devices	$333K	-	26/100